Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2‐Negative Luminal B Breast Cancer: A Prospective, Single‐Center, Single‐Arm, Phase II Trial (DANCER)

Documenti analoghi

• Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
  di: Xu Chen, et al.
  Pubblicazione: (2025)
• Triple HER2 Blockade With Trastuzumab, Pertuzumab, and Pyrotinib Versus Dual HER2 Blockade in the Neoadjuvant Treatment of HER2‐Positive Breast Cancer: A Randomized, Phase II Study
  di: Jiahui Huang, et al.
  Pubblicazione: (2026)
• Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer
  di: Yihua Huang, et al.
  Pubblicazione: (2024)
• Chimeric Antigen Receptor‐Macrophage Therapy Enters the Clinic: The First‐in‐Human Trial for HER2 + Solid Tumors
  di: Wenxue Ma, et al.
  Pubblicazione: (2025)
• Targeting CDK4/6 suppresses colorectal cancer by destabilizing YAP1
  di: Yalei Wen, et al.
  Pubblicazione: (2025)